The Ministry Of Health (KKM) has announced that the country will be the first in the world to receive conditional medication for treating Hepatitis C, known as Ravida® Tablet 200mg (Ravidasvir Hydrochloride 200mg).
According to a press release by KKM, Malaysia’s Drug Control Authority (DCA) is the first country to approve the usage of Ravida® as a combination with other medications to treat chronic cases of Hepatitis C (HCV) among adults.
The Hepatitis C (HCV) infection is a public health issue that KKM plans to overcome and eliminate by 2030. However, at the moment, the method of identification and treatment using the Direct Acting Antivirals (DAA) medication is too costly. Therefore, there is a need for alternative solutions in effectively treating the infection at a cost that is more affordable.
KKM also came up with a National Strategic Plan for 2019-2023 which aims to eliminate Hepatitis B and C.
In 2016, KKM worked together with Drugs for Neglected Diseases initiative (DNDi) to start an initiative collaboration to reduce any obstacles refraining HCV patients from getting treatment in Malaysia.
What do you guys think of this?
Also read: “She felt she wouldn’t wake up” M’sian Shares How His Pregnant Sister Died From Covid-19
